NCT01928381 - Safety, Tolerability and Preliminary Efficacy of AZD5213 in Combination With Pregabalin in Subjects With PDN and Good Pain Reporting Ability | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions

Diabetic Neuropathy, Painful; Diabetic Neuropathies

Interventions

DRUG

AZD5213 + pregabalin

Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)

DRUG

Placebo

Double blind placebo capsules to match AZD5213 and pregabalin

DRUG

pregabalin capsules

Double blind pregabalin capsules to match AZD5213 and placebo

Trial Locations (9)

Research Site, Clearwater

Research Site, Orlando

Research Site, Newnan

Research Site, Brockton

Research Site, Natick

Research Site, Watertown

Research Site, Winston-Salem

Research Site, Duncansville

Research Site, Philadelphia